Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.
Ontology highlight
ABSTRACT: Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile. We review the mechanism of action and clinical evidence of atezolizumab for metastatic urothelial blad
SUBMITTER: Aydin AM
PROVIDER: S-EPMC5352238 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA